Translational research in ovarian cancer: A must

International Journal of Gynecological Cancer

Volumn 13, Issue SUPPL. 2, 2003, Pages 220-230

  Hamilton, Thomas C ^a   Connolly, D C ^a   Nikitin, A Y ^b   Garson, K ^c   Vanderhyden, B C ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Etiology; Models; Surface epithelium

Indexed keywords

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER PATIENT; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; EARLY CANCER; FATALITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; OVARIAN NEOPLASMS;

EID: 1242342725     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2003.13350.x     Document Type: Conference Paper

References (132)

1. Papadaki L, Beilby JO. The fine structure of the surface epithelium of the human ovary. J Cell Sci 1971;8:445-65.
2. Blaustein A, Lee H. Surface cells of the ovary and pelvic peritoneum: a histochemical and ultrastructure comparison. Gynecol Oncol 1979;8:34-43.
3. Moore KL. The pelvis and perineum. In: Clinically Oriented Anatomy. Eds Satterfield TS, Napora L, Lumpkin K. Baltimore: Williams, Williams, 1992, 281-9.
4. Espey LL. Ultrastructure of the apex of the rabbit graafian follicle during the ovulatory process. Endocrinology 1967;81:267-76.
5. Ribeiro AF, Ferronha MH, David-Ferreira JF. Freeze-fracture study of the hamster ovary surface epithelium intercellular junctions. J Submicrosc Cytol 1983;15:415-23.
6. Perez RP, Godwin AK, Hamilton TC, Ozols RF. Ovarian cancer biology. Semin Oncol 1991;18:186-204.
7. Auersperg N. Culture and characterization of human ovarian surface epithelium. In: Ovarian Cancer: Methods and Protocols. Ed. Bartlett JMS. Totowa, NJ: Humana Press, 2000, 169-73.
8. Ivarsson K, Sundfeldt K, Brannstrom M, Janson PO. Production of steroids by human ovarian surface epithelial cells in culture: possible role of progesterone as growth inhibitor. Gynecol Oncol 2001;82:116-21.
9. Benjamin E, Law S, Bobrow LG. Intermediate filaments cytokeratin and vimentin in ovarian sex cord-stromal tumours with correlative studies in adult and fetal ovaries. J Pathol 1987;152:253-63.
10. Isola J, Kallioniemi OP, Korte JM et al. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol 1990;162:295-301.
11. Czernobilsky B, Moll R, Levy R, Franke WW. Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of the human ovary. Eur J Cell Biol 1985;37:175-90.
12. Jindal SK, Ishii E, Letarte M, Vera S, Teerds KJ, Dorrington JH. Regulation of transforming growth factor-α gene expression in an ovarian surface epithelial cell line derived from a human carcinoma. Biol Reprod 1995;52:1027-37.
13. Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC Jr. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol 1991;164:745-50.
14. Miettinen M, Lehto VP, Virtanen I. Expression of intermediate filaments in normal ovaries and ovarian epithelial, sex cord-stromal, and germinal tumors. Int J Gynecol Pathol 1983;2:64-71.
15. Nicosia SV, Johnson JH. Surface morphology of ovarian mesothelium (surface epithelium) and of other pelvic and extrapelvic mesothelial sites in the rabbit. Int J Gynecol Pathol 1984;3:249-60.
16. Blaustein A, Kaganowicz A, Wells J. Tumor markers in inclusion cysts of the ovary. Cancer 1982;49:722-6.
17. van Niekerk CC, Boerman OC, Ramaekers FC, Poels LG. Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas. Am J Pathol 1991;138:455-63.
18. Zeimet AG, Offner FA, Muller-Holzner E et al. Peritoneum and tissues of the female reproductive tract as physiological sources of CA-125. Tumour Biol 1998;19:275-82.
19. Nicosia SV. Neoplasms of the ovarian mesothelium. In: Path of Human Neoplasms. Ed. Azar HA. New York: Raven Press, 1988, 435-86.
20. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4:1-12.
21. Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983;2:275-85.
22. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001;276:27371-5.
23. Bjersing L, Cajander S. Ovulation and the mechanism of follicle rupture. V. Ultrastructure of tunica albuginea and theca externa of rabbit graafian follicles prior to induced ovulation. Cell Tissue Res 1974;153:15-30.
24. Ackerman RC, Murdoch WJ. Prostaglandin-induced apoptosis of ovarian surface epithelial cells. Prostaglandins 1993;45:475-85.
25. Osterholzer HO, Johnson JH, Nicosia SV. An autoradiographic study of rabbit ovarian surface epithelium before and after ovulation. Biol Reprod 1985;33:729-38.
26. Kruk PA, Auersperg N. Human ovarian surface epithelial cells are capable of physically restructuring extracellular matrix. Am J Obstet Gynecol 1992;167: 1437-43.
27. Kruk PA, Uitto VJ, Firth JD, Dedhar S, Auersperg N. Reciprocal interactions between human ovarian surface epithelial cells and adjacent extracellular matrix. Exp Cell Res 1994;215:97-108.
28. Gillett WR, Mitchell A, Hurst PR. A scanning electron microscopic study of the human ovarian surface epithelium: characterization of two cell types. Hum Reprod 1991;6:645-50.
29. Nicosia SV. The aging ovary. Med Clin North Am 1987; 71:1-9.
30. Hamilton TC. Ovarian cancer. Part I. Biology. Curr Probl Cancer 1992;16:1-57.
31. Blaustein A. Surface cells and inclusion cysts in fetal ovaries. Gynecol Oncol 1981;12:222-33.
32. Blaustein A, Kantius M, Kaganowicz A, Pervez N, Wells J. Inclusions in ovaries of females aged day 1-30 years. Int J Gynecol Pathol 1982;1:145-53.
33. Salazar H, Godwin AK, Daly MB et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996;88:1810-20.
34. Deligdisch L, Gil J. Characterization of ovarian dysplasia by interactive morphometry. Cancer 1989;63:748-55.
35. Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994;73:1859-64.
36. Scully RE. Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Int J Gynaecol Obstet 1995;49(Suppl.):S9-15.
37. Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, Demopoulos RI. Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol 1993;12:59-63.
38. Resta L, Russo S, Colucci GA, Prat J. Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 1993;82:181-6.
39. Fathalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet 1971;2:163.
40. Fathalla MF. Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv 1972;27:751-68.
41. Testa JR, Getts LA, Salazar H et al. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res 1994;54:2778-84.
42. Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev 1996;5:933-5.
43. Rodriguez GC, Walmer DK, Cline M et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998;5:271-6.
44. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-21.
45. Sell A, Bertelsen K, Andersen JE, Stroyer I, Panduro J. Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecol Oncol 1990;37:367-73.
46. Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH, Studd JW. Hormonal profiles after the menopause. Br Med J 1976;2:784-7.
47. Scaglia H, Medina M, Pinto-Ferreira AL, Vazques G, Gual C, Perez-Palacios G. Pituitary LH and FSH secretion and responsiveness in women of old age. Acta Endocrinol (Copenh) 1976;81:673-9.
48. Richardson SJ. The biological basis of the menopause. The menopause. In: Baillier's Clinical Endocrinology and Metabolism. Ed. Burger HG. Toronto: Baillere Tindall, 1993, 1-16.
49. Zheng W, Magid MS, Kramer EE, Chen YT. Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol 1996;148:47-53.
50. Konishi I, Kuroda H, Mandai M. Review: gonadotropins and development of ovarian cancer. Oncology 1999;57:45-8.
51. Kammerman S, Demopoulos RI, Raphael C, Ross J. Gonadotropic hormone binding to human ovarian tumors. Hum Pathol 1981;12:886-90.
52. Kobayashi F, Monma C, Nanbu K, Konishi I, Sagawa N, Mori T. Rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy. Gynecol Oncol 1996;62: 309-13.
53. Mandai M, Konishi I, Kuroda H et al. Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur J Cancer 1997;33:1501-7.
54. Emons G, Ortmann O, Pahwa GS, Hackenberg R, Oberheuser F, Schulz KD. Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH-agonists in ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992;155:31-8.
55. Godwin AK, Perez RP, Johnson SW, Hamaguchi K, Hamilton TC. Growth regulation of ovarian cancer. Hematol Oncol Clin North Am 1992;6:829-41.
56. Zheng W, Lu JJ, Luo F et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 2000;76:80-8.
57. Karlan BY, Jones J, Greenwald M, Lagasse LD. Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. Am J Obstet Gynecol 1995;173: 97-104.
58. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A 1999;96:5722-7.
59. Kuhnel R, de Graaff J, Rao BR, Stolk JG. Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem 1987;26:393-7.
60. Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC, van der Kwast TH. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol 1993;24:90-5.
61. Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, Scoccia B. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 1997;66:250-4.
62. Osterholzer HO, Streibel EJ, Nicosia SV. Growth effects of protein hormones on cultured rabbit ovarian surface epithelial cells. Biol Reprod 1985;33:247-58.
63. Davies BR, Finnigan DS, Smith SK, Ponder BA. Administration of gonadotropins stimulates proliferation of normal mouse ovarian surface epithelium. Gynecol Endocrinol 1999;13:75-81.
64. Wimalasena J, Dostal R, Meehan D. Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth. Gynecol Oncol 1992;46:345-50.
65. Kurbacher CM, Jager W, Kurbacher JA, Bittl A, Wildt L, Lang N. Influence of human luteinizing hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumour Biol 1995;16:374-84.
66. Simon WE, Albrecht M, Hansel M, Dietel M, Holzel F. Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 1983;70:839-45.
67. Kuroda H, Mandai M, Konishi I et al. Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of insulin-like growth factor-1 by hCG. Int J Cancer 1998;76:571-8.
68. Schiffenbauer YS, Abramovitch R, Meir G et al. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci U S A 1997;94:13203-8.
69. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC. Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2002;87:2245-53.
70. Gondos B. Surface epithelium of the developing ovary. Possible correlation with ovarian neoplasia. Am J Pathol 1975;81:303-21.
71. Hamilton TC, Davies P, Criffiths K. Steroid hormone receptor status of the normal and neoplastic ovarian surface germinal epithelium. In: Factors Regulating Ovarian Function. Eds Greenwald GS, Terranova PF. New York: Raven Press, 1983, 81-5.
72. Baldwin WS, Curtis SW, Cauthen CA, Risinger JI, Korach KS, Barrett JC. BG-1 ovarian cell line: an alternative model for examining estrogen-dependent growth in vitro. In Vitro Cell Dev Biol Anim 1998;34:649-54.
73. Nash JD, Ozols RF, Smyth JF, Hamilton TC. Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstet Gynecol 1989;73:1009-16.
74. Langdon SP, Hawkes MM, Lawrie SS et al. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br J Cancer 1990;62:213-6.
75. Wimalasena J, Meehan D, Dostal R, Foster JS, Cameron M, Smith M. Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors. Oncol Res 1993;5:325-37.
76. Langdon SP, Hirst GL, Miller EP et al. The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. J Steroid Biochem Mol Biol 1994;50:131-5.
77. Simpson BJ, Langdon SP, Rabiasz GJ et al. Estrogen regulation of transforming growth factor-α in ovarian cancer. J Steroid Biochem Mol Biol 1998;64:137-45.
78. Ridderheim M, Stendahl U, Backstrom T. Progesterone and estradiol stimulate release of epidermal growth factor/transforming growth factor-α by ovarian tumours in vitro. Anticancer Res 1994;14:2763-8.
79. Chien CH, Wang FF, Hamilton TC. Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells. Mol Cell Endocrinol 1994;99:11-9.
80. Rao BR, Slotman BJ. Endocrine factors in common epithelial ovarian cancer. Endocr Rev 1991;12:14-26.
81. Silva EG, Tornos C, Fritsche HA Jr et al. The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Mod Pathol 1997;10:879-83.
82. Boyd J, Hamilton TC, Berchuck A. Oncogenes and tumor-suppressor genes. In: Principles and Practice of Gynecologic Oncology. Eds Hoskins W, Perez C, Young R. Philadelphia: Lippincott, Williams, Wilkins, 2000.
83. Gallion HH, Pieretti M, DePriest PD, van Nagell JR Jr. The molecular basis of ovarian cancer. Cancer 1995; 76:1992-7.
84. Berchuck A, Kohler MF, Bast RC Jr. Molecular genetic features of ovarian cancer. Prog Clin Biol Res 1996;394: 269-84.
85. Matias-Guiu X, Prat J. Molecular pathology of ovarian carcinomas. Virchows Arch 1998;433:103-11.
86. Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. Int J Oncol 2000;16:567-76 [Review].
87. Shridhar V, Lee J, Pandita A et al. Genetic analysis of early-versus late-stage ovarian tumors. Cancer Res 2001;61:5895-904.
88. Schummer M, Ng WV, Bumgarner RE et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999;238:375-85.
89. Welsh JB, Zarrinkar PP, Sapinoso LM et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 2001;98:1176-81.
90. Hough CD, Sherman-Baust CA, Pizer ES et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000;60:6281-7.
91. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001;61:3869-76.
92. Sawiris GP, Sherman-Baust CA, Becker KG, Cheadle C, Teichberg D, Morin PJ. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res 2002;62:2923-8.
93. Tapper J, Butzow R, Wahlstrom T, Seppala M, Knuutila S. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. Br J Cancer 1997;75:1782-7.
94. Schwartz DR, Kardia SL, Shedden KA et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;62:4722-9.
95. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002;2:331-41.
96. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
97. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
98. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001;38:87-95.
99. Dodson MK, Cliby WA, Xu HJ et al. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res 1994;54:610-3.
100. Kim TM, Benedict WF, Xu HJ et al. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. Cancer Res 1994;54:605-9.
101. Gras E, Pons C, Machin P, Matias-Guiu X, Prat J. Loss of heterozygosity at the RB-1 locus and pRB immunostaining in epithelial ovarian tumors: a molecular, immunohistochemical, and clinicopathologic study. Int J Gynecol Pathol 2001;20:335-40.
102. Hashiguchi Y, Tsuda H, Yamamoto K, Inoue T, Ishiko O, Ogita S. Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum Pathol 2001;32:988-96.
103. Havrilesky LJ, Berchuck A. Molecular alterations in sporadic ovarian cancer. In: Ovarian Cancer. 2nd edn. Eds Rubin SC, Sutton GP. Philadelphia: Lippincott, Williams, Wilkins, 2001, 23-42.
104. Yarden RI, Brody LC. BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci U S A 1999;96:4983-8.
105. Aprelikova ON, Fang BS, Meissner EG et al. BRCA1-associated growth arrest is RB-dependent. Proc Natl Acad Sci U S A 1999;96:11866-71.
106. Deng CX, Brodie SG. Roles of BRCA1 and its interacting proteins. Bioessays 2000;22:728-37.
107. Anand N, Murthy S, Amann G et al. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 2002;31:301-5.
108. Zorn KK, Awtrey CS, Gardner GJ, Barrett JC, Boyd JA, Birrer MJ. Gene expression profiles of serous endometroid and clear cell subtypes of ovarian and endometrial cancer. Presented at the 34th Annual Meeting of the Society of Gynecologic Oncologists, 2003;90:117.
109. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 1997;57:850-6.
110. Hamilton TC, Fox H, Buckley CH, Henderson WJ, Griffiths K. Effects of talc on the rat ovary. Br J Exp Pathol 1984;65:101-6.
111. Abdollahi A, Bao R, Hamilton TC. LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein. Oncogene 1999;18:6477-87.
112. Abdollahi A, Getts LA, Sonoda G et al. Genome scanning detects amplification of the cathepsin B gene (CtsB) in transformed rat ovarian surface epithelial cells. J Soc Gynecol Investig 1999;6:32-40.
113. Abdollahi A, Godwin AK, Miller PD et al. Identification of a gene containing zinc-finger motifs based on lost expression in malignantly transformed rat ovarian surface epithelial cells. Cancer Res 1997;57: 2029-34.
114. Auersperg N, Maines-Bandiera S, Booth JH, Lynch HT, Godwin AK, Hamilton TC. Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer. Am J Obstet Gynecol 1995;173:558-65.
115. Roby KF, Taylor CC, Sweetwood JP et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000;21:585-91.
116. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002;1:53-62.
117. Orsulic S. An RCAS-TVA-based approach to designer mouse models. Mamm Genome 2002;13:543-7.
118. Godwin AK, Miller PD, Getts LA et al. Retroviral-like sequences specifically expressed in the rat ovary detect genetic differences between normal and transformed rat ovarian surface epithelial cells. Endocrinology 1995;136:4640-9.
119. Selvakumaran M, Bao R, Crijns AP, Connolly DC, Weinstein JK, Hamilton TC. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res 2001;61:1291-5.
120. Garson K, Macdonald EA, Dubé M, Bao R, Hamilton TC, Vanderhyden BC. Generation of tumors in transgenic mice expressing the SV40 T antigen under control of OSP-1 (ovarian specific promoter 1). J Soc Gynecol Investig 2003;10:244-50.
121. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
122. Josso N, di Clemente N, Gouedard L. Anti-müllerian hormone and its receptors. Mol Cell Endocrinol 2001;179: 25-32.
123. Teixeira J, Maheswaran S, Donahoe PK. Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev 2001;22:657-74.
124. Masiakos PT, MacLaughlin DT, Maheswaran S et al. Human ovarian cancer, cell lines, and primary ascites cells express the human müllerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res 1999;5:3488-99.
125. Connolly DC, Bao R, Nikitin AY et al. Female mice chimeric for expression of the SV40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003;63:1389-97.
126. Hanahan D. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985;315: 115-22.
127. Chen J, Tobin GJ, Pipas JM, Van Dyke T. T-antigen mutant activities in vivo: roles of p53 and pRB binding in tumorigenesis of the choroid plexus. Oncogene 1992;7:1167-75.
128. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci U S A 1994;91: 11236-40.
129. Greenberg NM, DeMayo F, Finegold MJ et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
130. Kasper S, Sheppard PC, Yan Y et al. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 1998;78:i-xv.
131. Grippo PJ, Sandgren EP. Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. Am J Pathol 2000; 157:805-13.
132. Chailley-Heu B, Rambaud C, Barlier-Mur AM et al. A model of pulmonary adenocarcinoma in transgenic mice expressing the simian virus 40 T antigen driven by the rat Calbindin-D9K (CaBP9K) promoter. J Pathol 2001;195:482-9.